Phenotypic studies on recombinant human immunodeficiency virus type 1 (HIV-1) containing CRF01_AE env gene derived from HIV-1-infected patient, residing in central Thailand.
Human immunodeficiency virus type 1 (HIV-1) env genes were cloned from blood samples of HIV-1-infected Thai patients, and 35 infectious CRF01_AE envelope glycoprotein (Env)-recombinant viruses were established. In this report, we examined the neutralization susceptibility of these viruses to human monoclonal antibodies, 2G12, IgG1 b12, 2F5 and 4E10, pooled patient plasma, coreceptor antagonists and fusion inhibitor, T-20. The neutralization susceptibility of CRF01_AE Env-recombinant viruses to 2F5, 4E10, patient plasma, coreceptor antagonists and T-20 varied, while most viruses showed low susceptibility to 2G12 and IgG1 b12. Several dual-tropic viruses showed lower susceptibility to 2F5 and 4E10 than CXCR4- or CCR5-tropic viruses. Neutralization susceptibility of the CRF01_AE Env-recombinant virus to pooled patient plasma was negatively correlated with the length of the V1/V2 region or the number of potential N-linked glycosylation sites in conserved regions of gp120. No correlation was found between the coreceptor usage and neutralization susceptibility of the virus to T-20, whereas several dual-tropic viruses showed higher susceptibility to coreceptor antagonists than CXCR4- or CCR5-tropic viruses. We propose that these CRF01_AE Env-recombinant viruses are useful to further study the molecular mechanism of the susceptibility of CRF01_AE Env to neutralizing antibodies and viral entry inhibitors.
Utachee
Piraporn
P
Thailand-Japan Research Collaboration Center on Emerging and Re-emerging Infections (RCC-ERI), Nonthaburi 11000, Thailand.
Jinnopat
Piyamat
P
Isarangkura-Na-Ayuthaya
Panasda
P
de Silva
U Chandimal
UC
Nakamura
Shota
S
Siripanyaphinyo
Uamporn
U
Wichukchinda
Nuanjun
N
Tokunaga
Kenzo
K
Yasunaga
Teruo
T
Sawanpanyalert
Pathom
P
Ikuta
Kazuyoshi
K
Auwanit
Wattana
W
Kameoka
Masanori
M
D000911:Antibodies, Monoclonal / Q000276:immunology; D000077560:Enfuvirtide; D015483:HIV Antibodies / Q000276:immunology; D015700:HIV Envelope Protein gp41 / Q000494:pharmacology; D023581:HIV Fusion Inhibitors / Q000494:pharmacology; D015658:HIV Infections / Q000821:virology*; D015497:HIV-1 / Q000235:genetics* / Q000254:growth & development* / Q000302:isolation & purification; D006801:Humans; D009500:Neutralization Tests; D010446:Peptide Fragments / Q000494:pharmacology; D015728:Receptors, HIV / Q000037:antagonists & inhibitors; D011995:Recombination, Genetic; D013785:Thailand; D054299:env Gene Products, Human Immunodeficiency Virus / Q000235:genetics*
D000911:Antibodies, Monoclonal; D015483:HIV Antibodies; D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors; D010446:Peptide Fragments; D015728:Receptors, HIV; D054299:env Gene Products, Human Immunodeficiency Virus; D000077560:Enfuvirtide